glp-1 agonist joint pain What to Know About Weight-Loss Drugs and Glucagon-like peptide-1 receptor agonists in
Description
Ren Y, Chen Y, Zheng W, Kong W, Liao Y, Zhang J, Wang M, Zeng T
All doses of orforglipron in the ATTAIN-2 trial demonstrated a dose-dependent reduction in body weight and HbA1c at 72 weeks, Nasreen Alfaris , MD, MPH, consultant at the Obesity, Endocrine and Metabolism Center at King Fahad Medical City in Riyadh, Saudi Arabia, said during a presentation
Pancreatitis: a potential complication of liraglutide
Based on drug class, GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025
